Hodgkin lymphoma (HL) treatment has dramatically improved, with high survival rates in early stages. However, long-term survivors face an increased risk of secondary cancers, particularly breast cancer (BC), which emerge as a leading cause of mortality decades after therapy.Background/Objectives: This study explores the risk of BC and the toxic effects of radiation therapy (RT) in long-term HL survivors compared to age-matched high-risk women, including BRCA1 and BRCA2 mutation carriers. A prospective study was conducted on 62 women who had undergone chemotherapy and involved-field RT for HL, with MRI used to assess breast tissue changes. This study’s primary endpoint was to analyze BC incidence in HL survivors, while secondary objectives focused on the analysis of background parenchymal enhancement (BPE) in irradiated areas.Results: The findings revealed a 5% incidence of BC in HL survivors, with 50% showing moderate or marked BPE, similar to that observed in high-risk BC controls. No significant differences in BPE distribution were found between the two groups.Conclusions: The study highlights the long-term risk of BC in HL survivors and suggests that advanced RT techniques and targeted therapies may help reduce the incidence of secondary tumors. Future research should focus on understanding the genetic and biological mechanisms behind treatment-induced cancers
霍奇金淋巴瘤（HL）的治疗已取得显著进展，早期患者生存率较高。然而，长期生存者面临继发性癌症风险增加的问题，尤其是乳腺癌（BC），这已成为治疗数十年后的主要死亡原因。 背景/目的：本研究旨在探讨长期HL生存者与年龄匹配的高风险女性（包括BRCA1和BRCA2突变携带者）相比，其乳腺癌风险及放射治疗（RT）的毒性效应。研究对62名接受过化疗及受累野放疗的HL女性患者进行了前瞻性分析，并采用磁共振成像（MRI）评估乳腺组织变化。本研究的主要终点是分析HL生存者的乳腺癌发病率，次要目标则侧重于分析放疗区域的背景实质强化（BPE）情况。 结果：研究发现HL生存者的乳腺癌发病率为5%，其中50%的患者表现出中度或显著的BPE，这与高风险乳腺癌对照组观察到的结果相似。两组之间的BPE分布未发现显著差异。 结论：该研究强调了HL生存者面临的长期乳腺癌风险，并指出先进的放疗技术和靶向治疗可能有助于降低继发性肿瘤的发病率。未来的研究应着重于理解治疗诱发癌症背后的遗传和生物学机制。
肿瘤(癌症)患者之家